Blankenhorn D H
Atherosclerosis Research Institute, University of Southern California School of Medicine, Los Angeles 90033.
Am J Med. 1991 Feb 21;90(2A):42S-47S. doi: 10.1016/0002-9343(91)90036-w.
Angiographic evidence of coronary artery atherosclerosis regression has been demonstrated in controlled clinical trials. The significance of this regression appears to depend in a complex way on the degree of atherosclerosis present when a regression regimen is initiated. Angiographic trials indicate that lesion change is a continuum, with a gradual transition from progression to stability and regression. Divergent lesion change can be seen in the same patient with a progression of some lesions and a regression of others. This makes it necessary to perform a comprehensive survey of all visible coronary segments when evaluating angiograms to determine the outcome of a clinical trial. An important finding in clinical trials is that new lesion formation can be reduced. This indicates that effective control of atherosclerosis may be possible with procedures now available, but noninvasive coronary artery imaging methods need to be refined.
在对照临床试验中已证实有冠状动脉粥样硬化消退的血管造影证据。这种消退的意义似乎以一种复杂的方式取决于开始采用消退方案时存在的动脉粥样硬化程度。血管造影试验表明,病变变化是一个连续过程,从进展到稳定和消退有一个逐渐的转变。在同一患者中可以看到不同的病变变化,一些病变进展而另一些病变消退。这使得在评估血管造影以确定临床试验结果时,有必要对所有可见的冠状动脉节段进行全面检查。临床试验中的一个重要发现是新病变形成可以减少。这表明利用现有的方法可能有效地控制动脉粥样硬化,但无创冠状动脉成像方法需要改进。